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Abstract 
Purpose: To evaluate the visual system of patients suffering from type I or VI 
mucopolysaccharidosis (MPS) by recording the visual evoked cortical potential (VECP).  
Methods: Two patients with MPS VI and 2 patients with MPS I were tested before and after 
enzyme replacement therapy (ERT). A control group of 20 subjects was tested for statistical 
comparison. VECP was elicited by monocular stimulation with 1-Hz phase-reversal 
checkerboard patterns at 0.5 and 2 cycles per degree and with 16° of visual field. In all 
patients, both eyes were tested. VECP amplitude and latency were measured and compared 
with tolerance limits obtained from controls.  
Results: MPS I and VI patients have a severe visual impairment that can be quantified by 
measuring VECPs. Even after several weeks of ERT, the visual impairment remained 
unaltered, indicating that the treatment had no significant influence on the visual conditions 
of MPS patients. Visual responses to high spatial frequencies were more deeply impaired 
than responses to low spatial frequencies. This can be explained by the kind of damage in 
the visual system that preferentially targets the eye optics.  
Conclusion: VECPs can be used to monitor the degree of visual impairment of MPS patients 
and to check ERT efficacy. Case Rep Ophthalmol 2012;3:104–112 
DOI: 10.1159/000337492 
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Introduction 
Mucopolysaccharidosis (MPS) are a rare group of inherited metabolic diseases with 
an incidence of about 1:25,000 in newborns worldwide and are characterized by the 
accumulation of complex molecules called glycosaminoglycans (GAG) in many tissues 
and organs. This accumulation is due to low or none lysosomal enzyme activity, which 
is needed for GAG catabolism [1]. About 11 different types of this disease have been 
identified and classified according to the defective enzyme. MPS patients present 
chronic and progressive clinical features, but symptoms may vary depending on each 
disease type. Organomegaly, multiplex dysostosis, hepatosplenomegaly, joint 
contractures, and characteristic facial changes are common findings of GAG tissue 
accumulation. Hearing dysfunctions, cardiorespiratory complications, low motility, and 
loss of visual acuity may also occur [1]. 
MPS VI visual dysfunction includes closed-angle and open-angle glaucoma [2] as well 
as optic nerve swelling and atrophy [3]. However, MPS I and VI visual acuity losses are 
generally associated with dermatan sulphate deposits in the cornea leading to an 
increase in the corneal thickness and corneal opacification [4, 5]. 
Enzyme replacement therapy (ERT) is an efficient MPS treatment based on the 
periodic replacement of the defective enzyme. ERT increases GAG degradation in 
tissues and significantly improves patients’ clinical condition; however, little is known 
about the ERT influence on patients’ vision [6, 7]. A recent study concluded that visual 
acuity and ocular findings had not deteriorated in 6 out of 7 MPS VI patients on ERT 
during a mean follow-up period of 3.5 years [8]. In the present study, we evaluated the 
visual system of children suffering from MPS I or VI by recording visual evoked cortical 
potentials (VECPs) [9]. 
Methods 
Subjects 
Four children were studied of whom 2 suffered from MPS VI (patients 1 and 2) and 2 from MPS I 
(patients 3 and 4). All patients had clinical manifestations of the disease and abnormally low 
lysosomal enzyme activity (table 1). VECP recordings were performed before ERT in all patients and 
after ERT in 3 of them (patients 1, 2, and 3). VECP recordings were also performed in healthy children 
(6 boys and 14 girls, 9.4 ± 2.2 years old) for statistical comparison. The eye refractive state was 
measured with an Automatic Refractor/Keratometer 599 (Zeiss Humphrey System, Dublin, Calif., 
USA) and then corrected to provide 20/20 visual acuity if necessary. Exclusion criteria comprised 
previous ocular, neural, or systemic diseases that could affect the visual system. 
Ethics 
This research was performed following the Brazilian and international regulations for ethics in 
research with human subjects (Ministério da Saúde, Brazil, 2000). It was reviewed and approved by 
the Research Ethics Committee, Tropical Medicine Nucleus, Federal University of Pará, Belém, Brazil 
(Report No. 045/2004 from June 30, 2004, and Report No. 103/2004 from November 4, 2004). 
ERT 
The recombinant enzymes laronidase (Aldurazyme®, recombinant human α-L-iduronidase; 
BioMarin Pharmaceutical, Novato, Calif., USA; Genzyme Corporation, Cambridge, Mass., USA) and 
arylsulphatase b (Naglazyme®; BioMarin Pharmaceutical) were intravenously administered once each 
week for 4 weeks (1 mg/kg for MPS I and 0.58 mg/kg for MPS VI, respectively). For patients 1 and 2, 
enzyme reposition started 2 years before VECP evaluation. For patients 3 and 4, enzyme reposition 
started 6 months before VECP evaluation. Case Rep Ophthalmol 2012;3:104–112 
DOI: 10.1159/000337492 
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Visual Stimulation and VECP Recording and Analysis 
All tests were performed monocularly. Visual stimulation, cortical recording, and signal analysis 
were previously described in details [10]. The methodology followed the ISCEV recommendations [9]. 
The stimulus consisted of 16 × 16° black and white checkerboards, 0.5 and 2 cycles per degree (cpd), 
100% Michelson contrast, and 50 cd/m2 mean luminance, presented at 1-Hz square-wave pattern-
reversal modulation. 
Gold-cup surface electrodes were used to obtain one-channel recordings from Oz (active 
electrode), Fp (reference electrode), and Fpz (ground) [9]. The signal was recorded and processed 
using a Cambridge Research System (CRS, Rochester, UK) setup comprising a MAS800 differential 
amplifier, an AS-1 data acquisition card, an IBM Pentium PC, and the Optima for Windows software. 
Low temporal frequency presentation mode evokes transient responses with 3 main components: 
N75, P100, and N135 [9]. We measured the latency for the N75 and P100 components, as well as the 
peak-to-peak amplitude of the P100-N75 and P100-N135 components. In some cases where the N75 
components were difficult to detect, the baseline-to-peak amplitude was measured. 
Statistical Analysis 
To characterize our control group, we calculated the mean, standard deviation, coefficient of 
variation, and the interquartile range for the latency and amplitude at both spatial frequencies. MPS 
subject responses were measured and compared to the statistical tolerance intervals for 95% 
confidence and 90% population coverage [11]. 
Results 
Normative Data 
VECP was recorded from 20 normal subjects. The N75 VECP component was 
measurable in 17 (85%) and 20 (100%) subjects at 0.5 and 2 cpd, respectively. The 
P100 VECP component was measurable at 0.5 and 2 cpd in all subjects. The N135 VECP 
component was measurable in 12 (60%) and 18 (90%) subjects at 0.5 and 2 cpd, 
respectively, and had a broad range of latency values, varying from 132.8 to 244.1 ms at 
0.5 cpd and from 142.6 to 219.7 ms at 2 cpd. Because of this variation, N135 
measurements were not used in the present study to evaluate the patient’s visual 
condition. 
Statistics 
Table 2 shows the mean, standard deviation, coefficient of variation, and 
interquartile range for N75 and P100 latencies, as well as the N75-P100 peak-to-peak 
amplitude for both spatial frequencies that were studied, 0.5 and 2 cpd. The latency 
varied less than the amplitude and was more useful for patient visual assessment. A 
statistically significant difference was observed for N75 and P100 latencies at both 0.5 
and 2 cpd (N75: F(4.12) = 26.44, P(0.05) = 1.05 × 10–5; P100: F(4.1) = 24.77, P(0.05) = 
1.43 × 10–5), and both components had longer latencies at 2 cpd. The N75-P100 
amplitude was not significantly different between the two spatial frequencies (N75-
P100: F(4.1) = 2.5, P(0.05) = 0.1). The large variation in the P100-N75 amplitude makes 
it less reliable for statistical comparison between patients and normal subjects [12]. 
Application of the Normative Data 
Fig. 1 and fig. 2 compare recordings obtained from MPS subjects (black and gray 
lines) with the grand mean recording from the control group (dotted lines) at 0.5 and 
2 cpd (see also table 2 for numerical data). Fig. 1a and b shows VECPs obtained from 
MPS I patients 3 and 4, respectively, who had not received any ERT when the 
recordings were made. N75 was impaired in both patients at both spatial frequencies. Case Rep Ophthalmol 2012;3:104–112 
DOI: 10.1159/000337492 
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P100 was impaired in patient 3 at both spatial frequencies and in patient 4 at 2 cpd. 
P100 had a normal amplitude and latency in patient 4 at 0.5 cpd. 
Fig. 2 shows recordings obtained from subjects submitted to ERT. Fig. 2a and b 
shows the data from MPS VI patients 1 and 2, respectively, 30 days after the single 
enzyme reposition given to these subjects. N75 was impaired in patient 1 at both 
spatial frequencies and was present with a low amplitude and longer latency than 
controls in patient 2. P100 was present in both patients with normal (0.5 cpd) or 
reduced (2 cpd) amplitude and delayed latency at most conditions. Fig. 2c and d shows 
the data from MPS I patient 3, 1 day after the second ERT and 68 days after the fourth 
ERT, respectively. All VECP components were impaired in this patient in the whole 
series of recordings made. No changes were found before or after ERT for this and all 
other patients (see also table 2). 
Discussion 
This study suggests that patients suffering from both MPS I and VI have a severe 
visual impairment that can be quantified by measuring cortical evoked responses 
elicited by different spatial frequencies. In addition, even after several weeks of ERT, 
the visual impairment remained unaltered, indicating that ERT had no significant 
influence on the visual condition of MPS patients. Although this was the case for this 
group of patients, it would be desirable in future studies to increase the number of 
patients to monitor possible improvement of visual functions using VECPs. 
In our patients, visual responses to a high spatial frequency (2 cpd) were more 
deeply impaired than responses to a low spatial frequency (0.5 cpd). This can be 
explained by the kind of damage in the visual system that preferentially targets the eye 
optics. The major systemic implications found in MPS patients are due to the deposition 
of GAG in many tissues and, consequently, the loss of function of many important 
organs [1, 13]. Dermatan sulphate is one of the most accumulated non-degraded GAG in 
corneal stroma and stromal keratocyte lysosomes of MPS I and VI patients [5]. The 
deposition of this compound in certain areas of the eye can promote a disruption of 
collagen fibrils responsible for the correct arrangement of visual structures, leading to 
corneal opacification. In addition, it can also increase intraocular pressure due to the 
blockade of anterior chamber structures, leading to ocular hypertension and glaucoma 
[14]. All these factors may contribute to a decrease in patients’ contrast sensitivity and 
visual acuity, independently of the clinical variations observed in each subtype of the 
disease. 
This study demonstrates that it is possible to investigate the visual functions of MPS 
patients through objective, accurate, low-cost, and noninvasive electrophysiology such 
as that provided by VECP recording. For instance, VECP recording is more comfortable 
for subjects such as MPS patients than ERG recording and other techniques that need to 
probe the eye. Previous studies indicated some electroretinographic alterations under 
dark adaptation condition [5] and loss of visual acuity due to corneal opacification [15]. 
Similarly to electroretinograms, standard VECPs elicited from the primary visual cortex 
provide a functional analysis of vision regardless of the etiology of the visual 
impairment. For a thorough clinical analysis, it is necessary to compare VECP results 
and clinical findings, such as corneal opacification, as well as biochemical data. In Case Rep Ophthalmol 2012;3:104–112 
DOI: 10.1159/000337492 
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agreement with the VECP results, corneal opacification remained unaltered after ERT in 
3 patients and was more intense in the remaining one. 
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Table 1. Summary of clinical and biochemical features of the MPS patients and ERT dosage 
 
 Clinical features of MPS patients 
                                Patient No. 
(MPS type) 
Age 
years 
Sex  PC  ASO 
months 
Blindness  Corneal  
opacification 
Heart disease 
                                1 (VI)  11  Female  No  14  No  +++  Mitral/aortic insufficiency 
2 (VI)  9  Female  No  24  No  ++  Mitral/aortic insufficiency 
3 (I)  18  Male  Yes  <6  No  ++++  Mitral/aortic insufficiency 
4 (I)  12  Male  No  60  No  ++  Mitral insufficiency 
                                 
 Biochemical analysis of MPS patients before ERT 
                    Patient No. 
(MPS type) 
Urinary GAG 
μg/mg creatinine 
Reference values 
μg/mg creatinine 
Leukocyte enzyme activity 
nM/h/mg protein 
Reference values 
nM/h/mg protein 
    1 (VI)  282.0  3.4–11  8.0  30–97 (ARSB) 
2 (VI)  238.0  3.4–11  10.0  30–97 (ARSB) 
3 (I)  313.8  1.5–7  0.03  13–62 (IDUA) 
4 (I)  298.9  3.4–11  0.25  30–97 (IDUA) 
                    PC = Parents’ consanguinity; ASO = age of symptom onset; ARSB = arylsulphatase b; IDUA = 
α-L-iduronidase. Corneal opacification: + = attenuated; ++ = mild; +++ = moderate; ++++ = severe.  
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Table 2. Descriptive statistics and normative data of VECP components at 0.5 and 2 cpd for the control 
group and MPS patients 
 
 Descriptive statistics 
                            SF    n  Mean  SD  CV, %  IQR 
                            0.5 cpd  Latency, ms           
  N75  17  76.8  3  3.9  74.2–77.2 
  P100  20  106.1  3.2  3  104–108.4 
  Amplitude, mv           
  N75-P100  20  27.1  11.4  42  18.1–34.9 
                            2 cpd  Latency, ms           
  N75  20  83.9  5  5.9  80.8–85.9 
  P100  20  114.2  6.6  5.8  109.4–116.2 
  Amplitude, mv           
  N75-P100  20  21.4  11.4  53.2  10.7–28.2 
                             
 Normative data of VECP parameters and values of MPS patients 
              Latency, ms 
    N75  P100 
    Tolerance interval  0.5 cpd  69.7–83.9  98.7–113.4 
  2 cpd  72.4–95.3  99.2–129.2 
                Patient 1 (MPS VI)  0.5 cpd  NR (RE), NR (LE)  115.2* (RE), 114.3* (LE) 
  2 cpd  NR (RE), NR (LE)  129.9* (RE), 142.6* (LE) 
                Patient 2 (MPS VI)  0.5 cpd  89.8* (RE), 89.8* (LE)   110.4 (RE), 114.3* (LE) 
  2 cpd  100.6* (RE), 99.6* (LE)  130.9* (RE), 127 (LE) 
                Patient 3 (MPS I)  0.5 cpd  NR (RE), NR (LE)  NR (RE), NR(LE) 
  2 cpd  NR (RE), NR (LE)  NR (RE), NR (LE) 
                Patient 3 – 2R (MPS I)  0.5 cpd  NR (RE), NR (LE)  NR (RE), NR (LE) 
  2 cpd  NR (RE), NR (LE)  NR (RE), NR (LE) 
                Patient 3 – 4R (MPS I)  0.5 cpd  NR (RE), NR (LE)  NR (RE), NR (LE) 
  2 cpd  NR (RE), NR (LE)  NR (RE), NR (LE) 
                Patient 4 (MPS I)  0.5 cpd  NR (RE), NR (LE)  110.4 (RE), 111.3 (LE) 
  2 cpd  NR (RE), NR (LE)  NR (RE), NR (LE) 
                SF = Spatial frequency; SD = standard deviation; CV = coefficient of variation; IQR = interquartile range; 
2R = second ERT; 4R = fourth ERT; RE = right eye; LE = left eye; NR = no response. * Value outside the 
tolerance interval. 
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Fig. 1. VECPs from MPS patients at 0.5 and 2 cpd. a MPS I patient 3. b MPS I patient 4. None of the 
subjects were on ERT at the moment of recordings. Dotted lines represent the grand mean 
recordings from the control group. Bold and gray lines represent recordings obtained by stimulating 
the patients’ right or left eye, respectively. 
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Fig. 2. VECPs from MPS patients. a, b MPS VI patients 1 and 2, respectively, 30 days after the unique 
enzyme reposition given to these subjects. c, d MPS I patient 3 1 day after the second enzyme 
reposition (a) and 68 days after the fourth reposition (b) at the two spatial frequencies studied, 0.5 
and 2 cpd. Dotted lines represent the grand mean recordings from the control group. Bold and gray 
lines represent recordings obtained by stimulating the patients’ right and left eye, respectively. 
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